Bellerophon to Present at the JMP Securities Life Sciences Conference

WARREN, N.J., June 13, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, announced today that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the JMP Securities Life Sciences Conference, being held June 19-20, 2019, at the St. Regis New York Hotel in New York City.

Bellerophon Presentation Details
Date:				Thursday, June 20
Time:				11:00 AM Eastern Time
Location:				St. Regis New York Hotel, New York, NY
Webcast:				http://wsw.com/webcast/jmp39/blph/

About BellerophonBellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system.  For more information, please visit www.bellerophon.com.

Contacts
At Bellerophon:				At LifeSci Advisors:
Fabian Tenenbaum, Chief Executive Officer				Brian Ritchie
(908) 574-4767				(212) 915-2578
				[email protected]

Source: Bellerophon Therapeutics, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Family Federation for World Peace and Unification Leads Hundreds in Las Vegas Prayer Vigil for the Mother of Peace Ahead of South Korea Verdict
• SOL Leads Fresh Large-Cap Momentum as IceBull’s Live Stage 1 Sale Builds Its Best Crypto Presale 2026 Case
• Atlas Advisor Brings AI-Native PID Tuning Diagnostics to Plant Floors